The third quarter finished with 12 IPOs raising $1.2 billion, tied for the most active week of the year. Returns varied, but the group averaged a gain of just 1.0%. Not surprising, SurveyMonkey (SVMK) was the week's top performer,...read more
The market has been unenthusiastic about novel antibiotics, and Entasis Therapeutics proved susceptible on Wednesday. The company fell 28.9%...read more
Entasis Therapeutics Holdings, a Phase 2 biotech developing therapies for multi-drug resistant bacteria, raised $75 million by offering 5.0 million shares at $15, below the range of $16 to $18. Entasis had planned to raise $75 million by offering 4.4...read more
We're looking at as many as 13 IPOs in the upcoming week, raising up to $1.1 billion. Even if 2 are postponed, it will still be the busiest September by IPO count since 2000. The 13 offerings are relatively small: none plan to raise more than $200 million, and...read more
US IPO Weekly Recap: 12 IPOs wrap up active third quarter as SurveyMonkey pops 34%
The third quarter finished with 12 IPOs raising $1.2 billion, tied for the most active week of the year. Returns varied, but the group averaged a gain of just 1.0%. Not surprising, SurveyMonkey (SVMK) was the week's top performer,...read more
Entasis Therapeutics plummets 29% in worst biotech debut since 2002
The market has been unenthusiastic about novel antibiotics, and Entasis Therapeutics proved susceptible on Wednesday. The company fell 28.9%...read more
Entasis Therapeutics prices IPO below the range at $15; upsized offering yields $75 million
Entasis Therapeutics Holdings, a Phase 2 biotech developing therapies for multi-drug resistant bacteria, raised $75 million by offering 5.0 million shares at $15, below the range of $16 to $18. Entasis had planned to raise $75 million by offering 4.4...read more
US IPO Week Ahead: 13 IPOs close out 3rd quarter with biotechs, China and SurveyMonkey
We're looking at as many as 13 IPOs in the upcoming week, raising up to $1.1 billion. Even if 2 are postponed, it will still be the busiest September by IPO count since 2000. The 13 offerings are relatively small: none plan to raise more than $200 million, and...read more